These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
406 related articles for article (PubMed ID: 37240292)
1. Interrelationship between COVID-19 and Coagulopathy: Pathophysiological and Clinical Evidence. Ragnoli B; Da Re B; Galantino A; Kette S; Salotti A; Malerba M Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240292 [TBL] [Abstract][Full Text] [Related]
2. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. Acanfora D; Acanfora C; Ciccone MM; Scicchitano P; Bortone AS; Uguccioni M; Casucci G Viruses; 2021 Sep; 13(10):. PubMed ID: 34696334 [TBL] [Abstract][Full Text] [Related]
3. Impaired coagulation, liver dysfunction and COVID-19: Discovering an intriguing relationship. D'Ardes D; Boccatonda A; Cocco G; Fabiani S; Rossi I; Bucci M; Guagnano MT; Schiavone C; Cipollone F World J Gastroenterol; 2022 Mar; 28(11):1102-1112. PubMed ID: 35431501 [TBL] [Abstract][Full Text] [Related]
4. [Peculiarities of blood coagulation disorders in patients with COVID-19]. Evtugina NG; Sannikova SS; Peshkova AD; Safiullina SI; Andrianova IA; Tarasova GR; Khabirova AI; Rumyantsev AG; Ataullakhanov FI; Litvinov RI Ter Arkh; 2021 Nov; 93(11):1255-1263. PubMed ID: 36286646 [TBL] [Abstract][Full Text] [Related]
5. Coagulopathy during COVID-19 infection: a brief review. Cunningham RM; Johnson Moore KL; Moore JS Clin Exp Med; 2023 Jul; 23(3):655-666. PubMed ID: 36121504 [TBL] [Abstract][Full Text] [Related]
6. COVID-19 coagulopathy - what should we treat? Chowdary P Exp Physiol; 2022 Jul; 107(7):749-758. PubMed ID: 35733235 [TBL] [Abstract][Full Text] [Related]
7. Complement activation and coagulopathy - an ominous duo in COVID19. Tomo S; Kumar KP; Roy D; Sankanagoudar S; Purohit P; Yadav D; Banerjee M; Sharma P; Misra S Expert Rev Hematol; 2021 Feb; 14(2):155-173. PubMed ID: 33480807 [TBL] [Abstract][Full Text] [Related]
8. Haematological manifestations of COVID-19: From cytopenia to coagulopathy. Agbuduwe C; Basu S Eur J Haematol; 2020 Nov; 105(5):540-546. PubMed ID: 32663356 [TBL] [Abstract][Full Text] [Related]
9. COVID-19: coagulation disorders and anticoagulant treatment in patients hospitalised in ICU. Pluta J; Cieniewicz A; Trzebicki J Anaesthesiol Intensive Ther; 2021; 53(2):153-161. PubMed ID: 34006056 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 associated coagulopathy and thrombosis in cancer. Levi M; van Es N Thromb Res; 2022 May; 213 Suppl 1():S72-S76. PubMed ID: 36210564 [TBL] [Abstract][Full Text] [Related]
11. Coagulopathy in COVID-19 and anticoagulation clinical trials. Zhang H; Lao Q; Zhang J; Zhu J Best Pract Res Clin Haematol; 2022 Sep; 35(3):101377. PubMed ID: 36494146 [TBL] [Abstract][Full Text] [Related]
12. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Iba T; Connors JM; Levy JH Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567 [TBL] [Abstract][Full Text] [Related]
15. Thromboelastography clot strength profiles and effect of systemic anticoagulation in COVID-19 acute respiratory distress syndrome: a prospective, observational study. Bocci MG; Maviglia R; Consalvo LM; Grieco DL; Montini L; Mercurio G; Nardi G; Pisapia L; Cutuli SL; Biasucci DG; Gori C; Rosenkranz R; De Candia E; Carelli S; Natalini D; Antonelli M; Franceschi F Eur Rev Med Pharmacol Sci; 2020 Dec; 24(23):12466-12479. PubMed ID: 33336766 [TBL] [Abstract][Full Text] [Related]
16. COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Salabei JK; Fishman TJ; Asnake ZT; Ali A; Iyer UG Heart Lung; 2021; 50(2):357-360. PubMed ID: 33524866 [TBL] [Abstract][Full Text] [Related]
17. Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines. Abdel-Bakky MS; Amin E; Ewees MG; Mahmoud NI; Mohammed HA; Altowayan WM; Abdellatif AAH Viruses; 2022 Jan; 14(2):. PubMed ID: 35215822 [TBL] [Abstract][Full Text] [Related]
18. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052 [TBL] [Abstract][Full Text] [Related]
19. Coagulation abnormalities & thromboprophylaxis in COVID-19. Jandial A; Gupta A; Malviya A; Agastam S; Kumar D Indian J Med Res; 2021 May&Jun; 153(5&6):606-618. PubMed ID: 34643567 [TBL] [Abstract][Full Text] [Related]
20. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]